Sensei Biotherapeutics FY EPS $(1.22) Up From $(1.58) YoY; 2023 Year End Cash, Cash Equivalents And Marketable Securities Of $65.8M Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025
Sensei Biotherapeutics FY EPS $(1.22) Up From $(1.58) YoY; 2023 Year End Cash, Cash Equivalents And Marketable Securities Of $65.8M Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025
Sensei Biotherapeutics财年每股收益为1.22美元，高于同比1.58美元；2023年年终现金、现金等价物和有价证券的6,580万美元预计将为2025年第四季度提供现金流
Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(1.22) per share. This is a 22.78 percent increase over losses of $(1.58) per share from the same period last year.
Sensei Biotherapeutics（纳斯达克股票代码：SNSE）公布的季度亏损为每股1.22美元。这比去年同期每股亏损1.58美元（1.58美元）增长了22.78％。